Companies Lantheus Holdings, Inc.
Lantheus (LNTH): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Lantheus Holdings, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers1st pct.Of 18 peer CEOs
CEO pay, last three years
- $12,578,845FY2023
- $787,596FY2024
- $2,173,930FY2025
CEO total pay was $2,173,930 in fiscal 2025, up from $787,596 in fiscal 2024.
FY2025: salary $100,000 · bonus $0 · stock awards $749,963 · option awards $749,999
Executives and directors
Daniel Niedzwiecki · General CounselAmanda Morgan · CCOPaul Blanchfield · PresidentBrian Markison · Chief Executive OfficerLudger Dinkelborg · ExecutiveRobert Marshall Jr. · CFOMary Anne Heino · CEODr. Gérard Ber · Independent DirectorDr. James H. Thrall · Independent DirectorDr. Phuong Khanh (P.K.) Morrow · Independent DirectorGary J. Pruden · Independent DirectorHeinz Mäusli · Independent DirectorJulie Eastland · Independent DirectorJulie McHugh · Lead Independent DirectorMinnie Baylor-Henry · Independent DirectorSamuel Leno · Independent Director
Frequently asked questions
Who was the highest-paid executive at Lantheus Holdings, Inc. in fiscal 2025?
As disclosed, Ludger Dinkelborg (Head of Research and Development) was the highest-paid executive at Lantheus Holdings, Inc. in fiscal 2025, with total compensation of $15,259,597.
How does Lantheus Holdings, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Mary Anne Heino's total compensation ranked at the 1st percentile of Lantheus Holdings, Inc.'s disclosed peer group.
What is Lantheus Holdings, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Lantheus Holdings, Inc.'s CEO-to-median employee pay ratio was 79:1.
How did shareholders vote on Lantheus Holdings, Inc.'s executive compensation?
As disclosed, 96.54% of shareholders supported Lantheus Holdings, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Lantheus Holdings, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Lantheus Holdings, Inc. reported total board compensation of $2,631,115 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Ludger Dinkelborg | $227,716 | $0 | $799,968 | $799,985 | $13,410,752 | $0 | $21,176 | $15,259,597 |
| Head of Research and Development | ||||||||
| Brian Markison | 990,385 | 0 | 10,104,081 | 2,374,972 | 434,775 | 0 | 15,525 | 13,919,738 |
| Former Chief Executive Officer | ||||||||
| Paul Blanchfield | 693,333 | 0 | 3,828,938 | 899,970 | 0 | 0 | 13,034 | 5,435,275 |
| Former President | ||||||||
| Robert Marshall Jr. | 697,840 | 0 | 3,403,332 | 799,967 | 277,877 | 0 | 15,948 | 5,194,964 |
| Chief Financial Officer and Treasurer | ||||||||
| Daniel Niedzwiecki | 588,816 | 0 | 3,403,332 | 799,967 | 156,860 | 0 | 17,409 | 4,966,384 |
| Chief Administrative Officer, General Counsel and Corporate Secretary | ||||||||
| Amanda Morgan | 541,977 | 0 | 2,127,140 | 499,958 | 107,906 | 0 | 27,566 | 3,304,547 |
| Chief Commercial Officer | ||||||||
| Mary Anne Heino | 100,000 | 0 | 749,963 | 749,999 | 0 | 0 | 573,968 | 2,173,930 |
| Executive Chairperson and Chief Executive Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Ludger Dinkelborg | $15,259,597 | — | — | — |
| Brian Markison | 13,919,738 | 13,400,697 | — | ↑ +519,041 |
| Paul Blanchfield | 5,435,275 | 5,307,884 | 5,305,240 | ↑ +127,391 |
| Robert Marshall Jr. | 5,194,964 | 5,434,796 | 4,326,011 | ↓ −239,832 |
| Daniel Niedzwiecki | 4,966,384 | 4,352,332 | 3,115,728 | ↑ +614,052 |
| Amanda Morgan | 3,304,547 | 2,808,706 | — | ↑ +495,841 |
| Mary Anne Heino | 2,173,930 | 787,596 | 12,578,845 | ↑ +1,386,334 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The core philosophy of our executive compensation program is to support our primary objective of being the leading radiopharmaceutical-focused company committed to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes.
| CEO STI target (% of salary) | 110% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Amanda Morgan | OPTION | 2025-03-05 | — | — | 8,704 | — | $499,958 |
| Daniel Niedzwiecki | RSU | 2025-03-05 | — | — | 7,961 | — | 799,921 |
| Paul Blanchfield | RSU | 2025-03-05 | — | — | 8,957 | — | 899,999 |
| Amanda Morgan | RSU | 2025-03-05 | — | — | 4,976 | — | 499,988 |
| Mary Anne Heino | OPTION | 2025-11-17 | — | — | 26,325 | — | 749,999 |
| Robert Marshall Jr. | RSU | 2025-03-05 | — | — | 7,961 | — | 799,921 |
| Brian Markison | PSU | 2025-03-05 | 23,636 | 47,273 | — | 94,546 | 7,729,136 |
| Paul Blanchfield | OPTION | 2025-03-05 | — | — | 15,668 | — | 899,970 |
| Robert Marshall Jr. | PSU | 2025-03-05 | 7,961 | 15,923 | — | 31,846 | 2,603,411 |
| Brian Markison | RSU | 2025-03-05 | — | — | 23,636 | — | 2,374,945 |
| Paul Blanchfield | PSU | 2025-03-05 | 8,957 | 17,914 | — | 35,828 | 2,928,939 |
| Amanda Morgan | PSU | 2025-03-05 | 4,976 | 9,952 | — | 19,904 | 1,627,152 |
| Ludger Dinkelborg | OPTION | 2025-08-15 | — | — | 25,324 | — | 799,985 |
| Robert Marshall Jr. | OPTION | 2025-03-05 | — | — | 13,927 | — | 799,967 |
| Brian Markison | OPTION | 2025-03-05 | — | — | 41,347 | — | 2,374,972 |
| Mary Anne Heino | RSU | 2025-11-17 | — | — | 14,285 | — | 749,963 |
| Ludger Dinkelborg | RSU | 2025-08-15 | — | — | 14,765 | — | 799,968 |
| Daniel Niedzwiecki | PSU | 2025-03-05 | 7,961 | 15,923 | — | 31,846 | 2,603,411 |
| Daniel Niedzwiecki | OPTION | 2025-03-05 | — | — | 13,927 | — | 799,967 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Amanda Morgan | $499,988 | $1,627,152 | $499,958 | 61.9% |
| Daniel Niedzwiecki | 799,921 | 2,603,411 | 799,967 | 61.9% |
| Paul Blanchfield | 899,999 | 2,928,939 | 899,970 | 61.9% |
| Mary Anne Heino | 749,963 | 0 | 749,999 | 0.0% |
| Robert Marshall Jr. | 799,921 | 2,603,411 | 799,967 | 61.9% |
| Brian Markison | 2,374,945 | 7,729,136 | 2,374,972 | 61.9% |
| Ludger Dinkelborg | 799,968 | 0 | 799,985 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Amanda Morgan | RSU | 150 | — | $9,983 |
| Daniel Niedzwiecki | RSU | 367 | — | 24,424 |
| Daniel Niedzwiecki | Option | 654 | 89.16 | — |
| Daniel Niedzwiecki | RSU | 1,372 | — | 91,307 |
| Robert Marshall Jr. | RSU | 1,624 | — | 108,077 |
| Robert Marshall Jr. | RSU | 2,254 | — | 150,004 |
| Daniel Niedzwiecki | Option | 2,399 | 73.35 | — |
| Mary Anne Heino | RSU | 2,537 | — | 168,837 |
| Amanda Morgan | RSU | 3,868 | — | 257,415 |
| Robert Marshall Jr. | Option | 3,941 | 73.35 | — |
| Daniel Niedzwiecki | PSU | 4,402 | — | 292,953 |
| Mary Anne Heino | Option | 4,543 | 78.81 | — |
| Amanda Morgan | RSU | 4,976 | — | 331,153 |
| Daniel Niedzwiecki | RSU | 6,768 | — | 450,410 |
| Amanda Morgan | Option | 6,874 | 64.64 | — |
| Robert Marshall Jr. | RSU | 7,961 | — | 529,805 |
| Daniel Niedzwiecki | RSU | 7,961 | — | 529,805 |
| Robert Marshall Jr. | RSU | 8,122 | — | 540,519 |
| Mary Anne Heino | RSU | 8,521 | — | 567,073 |
| Amanda Morgan | Option | 8,704 | 100.48 | — |
| Amanda Morgan | PSU | 8,860 | — | 589,633 |
| Daniel Niedzwiecki | Option | 12,029 | 64.64 | — |
| Robert Marshall Jr. | Option | 13,927 | 100.48 | — |
| Daniel Niedzwiecki | Option | 13,927 | 100.48 | — |
| Mary Anne Heino | RSU | 14,285 | — | 950,667 |
| Robert Marshall Jr. | Option | 14,435 | 64.64 | — |
| Ludger Dinkelborg | RSU | 14,765 | — | 982,611 |
| Mary Anne Heino | Option | 14,899 | 73.35 | — |
| Daniel Niedzwiecki | PSU | 16,462 | — | 1,095,546 |
| Amanda Morgan | PSU | 19,904 | — | 1,324,611 |
| Amanda Morgan | PSU | 23,204 | — | 1,544,226 |
| Brian Markison | RSU | 23,636 | — | 1,572,976 |
| Ludger Dinkelborg | Option | 25,324 | 54.18 | — |
| Mary Anne Heino | Option | 26,325 | 52.5 | — |
| Robert Marshall Jr. | PSU | 27,044 | — | 1,799,778 |
| Robert Marshall Jr. | PSU | 31,846 | — | 2,119,351 |
| Daniel Niedzwiecki | PSU | 31,846 | — | 2,119,351 |
| Daniel Niedzwiecki | PSU | 40,608 | — | 2,702,462 |
| Brian Markison | Option | 41,347 | 100.48 | — |
| Brian Markison | RSU | 43,832 | — | 2,917,020 |
| Robert Marshall Jr. | PSU | 48,730 | — | 3,242,982 |
| Brian Markison | PSU | 94,546 | — | 6,292,036 |
| Mary Anne Heino | PSU | 102,248 | — | 6,804,604 |
| Brian Markison | PSU | 131,496 | — | 8,751,059 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Dr. Phuong Khanh (P.K.) MorrowIndependent · Science and Technology · Talent and Compensation · Newly elected | $54,792 | $249,885 | $249,983 | $0 | $0 | $554,660 |
| Julie McHughIndependent · Lead Independent Director · Nominating and Corporate Governance (Chair) | 152,660 | 199,941 | 199,983 | 0 | 0 | 552,584 |
| Gary J. PrudenIndependent · Audit · Talent and Compensation (Chair) | 92,500 | 199,941 | 199,983 | 0 | 0 | 492,424 |
| Samuel LenoIndependent · Audit (Chair) | 89,375 | 199,941 | 199,983 | 0 | 0 | 489,299 |
| Dr. James H. ThrallIndependent · Nominating and Corporate Governance · Science and Technology (Chair) | 89,000 | 199,941 | 199,983 | 0 | 0 | 488,924 |
| Minnie Baylor-HenryIndependent · Nominating and Corporate Governance · Science and Technology | 80,833 | 199,941 | 199,983 | 0 | 0 | 480,757 |
| Heinz MäusliIndependent · Audit · Nominating and Corporate Governance | 80,000 | 199,941 | 199,983 | 0 | 0 | 479,924 |
| Julie EastlandIndependent · Audit · Talent and Compensation | 76,667 | 199,941 | 199,983 | 0 | 0 | 476,591 |
| Dr. Gérard BerIndependent · Talent and Compensation · Science and Technology | 65,875 | 199,941 | 199,983 | 0 | 0 | 465,799 |
| Brian A. MarkisonEmployee director · Not standing for re-election · Departed during FY | 0 | 0 | 0 | — | 0 | 15,525 |
| Mary Anne HeinoEmployee director · Board Chair · Science and Technology | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $100,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 16,000 |
| Stock ownership guideline | $300,000 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $781,702 |
| Equity awards (grant-date value) | $1,849,413 |
| All other compensation | $0 |
| Total cost of the board | $2,631,115 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Lantheus as a peer
Companies that benchmark against LNTH
12 companies name LNTH as a compensation peer
- ACCURAY INCARAYFY2026
- AVANOS MEDICAL, INC.AVNSFY2025
- BIO-RAD LABORATORIES, INC.BIOFY2025
- Cryoport, Inc.CYRXFY2025
- GLAUKOS CorpGKOSFY2025
- Inspire Medical Systems, Inc.INSPFY2025
- iRhythm Holdings, Inc.IRTCFY2025
- MARAVAI LIFESCIENCES HOLDINGS, INC.MRVIFY2025
- MERIT MEDICAL SYSTEMS INCMMSIFY2025
- Mirion Technologies, Inc.MIRFY2025
- Penumbra IncPENFY2025
- TELEFLEX INCTFXFY2025
Each company listed discloses LNTH in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named LNTH in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
AZTA AzentaBIO Bio-Rad LaboratoriesTECH Bio-TechneBMRN BioMarin PharmaceuticalEXAS Exact SciencesHAE HaemoneticsIONS Ionis PharmaceuticalsNBIX Neurocrine BiosciencesSRPT Sarepta TherapeuticsALKS AlkermesACAD Acadia PharmaceuticalsBRKR BrukerRGEN RepligenHALO Halozyme TherapeuticsAPLS Apellis PharmaceuticalsEXEL ExelixisWAT WatersUTHR United Therapeutics
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Halozyme Therapeutics | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 3 | BioMarin Pharmaceutical | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 4 | United Therapeutics | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 5 | Exact Sciences | 2024 | Kevin Conroy | 1,083,368 | 13,496,138 | 0 | 712,329 | 15,539,378 |
| 6 | Waters | 2025 | Udit Batra | 1,150,000 | 7,430,247 | 2,999,922 | 2,371,875 | 13,973,044 |
| 7 | Neurocrine Biosciences | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 8 | Ionis Pharmaceuticals | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 9 | Haemonetics | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 10 | Apellis Pharmaceuticals | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 11 | Azenta | 2025 | John Marotta | 900,000 | 8,386,297 | 0 | 1,063,656 | 10,371,414 |
| 12 | Acadia Pharmaceuticals | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 13 | Bio-Techne | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 14 | Bio-Rad Laboratories | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 15 | Alkermes | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 16 | Sarepta Therapeutics | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 17 | Repligen | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
| 18 | Bruker | 2025 | Frank Laukien | 976,554 | 1,623,407 | 1,488,109 | 587,270 | 4,706,388 |
| 19 | Lantheus Holdings, Inc. | 2025 | Mary Anne Heino | 100,000 | 749,963 | 749,999 | 0 | 2,173,930 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Lantheus Holdings, Inc. | 47% | PSU 50 · RSU 25 · Options 25 | Yes — relative Total Shareholder Return (rTSR) against the S&P 400 Health Care Index | Pearl Meyer |
| Acadia Pharmaceuticals | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Alkermes | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Apellis Pharmaceuticals | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Azenta | not disclosed | PSU 50 · RSU 50 | Yes — Relative TSR (rTSR) | Pearl Meyer |
| Bio-Rad Laboratories | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| Bio-Techne | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon |
| BioMarin Pharmaceutical | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Bruker | 43.0% | RSU 52 · Options 48 | not disclosed | Aon's Human Capital Solutions Practice |
| Exact Sciences | 47% | PSU 60 · RSU 40 | No | Aon |
| Exelixis | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Haemonetics | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Halozyme Therapeutics | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Ionis Pharmaceuticals | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Neurocrine Biosciences | 105% | Option 50 · PRSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Repligen | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| Sarepta Therapeutics | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| United Therapeutics | 221% | PSO 50 · PSU 50 | No | Aon |
| Waters | 110% | PSU 50 · Options 35 · RSU 15 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-04-30 | 54,068,553 | 1,936,862 | 52,554 | 96.54% | Passed |
| 2025 | 2025-05-01 | 57,776,739 | 2,835,657 | 169,219 | 95.32% | Passed |
| 2024 | 2024-04-25 | 56,633,104 | 1,349,898 | 124,439 | 97.67% | Passed |
| 2023 | 2023-04-27 | 56,744,221 | 1,207,246 | 80,365 | 97.92% | Passed |
| 2022 | 2022-04-28 | 58,722,087 | 492,862 | 31,466 | 99.17% | Passed |
| 2021 | 2021-04-28 | 48,767,237 | 2,041,652 | 2,504,865 | 95.98% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-04-30 | 96.54%a |
| 2025 | 2025-05-01 | 95.32%b |
| 2024 | 2024-04-25 | 97.67%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the voting of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the voting of this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the voting of this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 79 : 1 |
|---|---|
| CEO total compensation | $15,307,866 |
| Median employee compensation | $194,254 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Daniel Niedzwiecki | See Remarks | 2026-04-17 | D | 1,911 | $84 | $160,180 | Common | Form 4 ↗ |
| Julie Eastland | Director | 2026-05-14 | A | 4,137 | 0 | 0 | Common | Form 4 ↗ |
| Dr. James H. Thrall | Director | 2026-05-14 | A | 4,137 | 0 | 0 | Common | Form 4 ↗ |
| Mary Anne Heino | Director | 2026-05-14 | D | 1,227 | 97 | 118,614 | Common | Form 4 ↗ |
| Dr. Gérard Ber | Director | 2026-05-14 | D | 381 | 97 | 36,831 | Common | Form 4 ↗ |
| Dr. Gérard Ber | Director | 2026-05-14 | A | 4,137 | 0 | 0 | Common | Form 4 ↗ |
| Heinz Christoph Maeusli | Director | 2026-05-14 | A | 4,137 | 0 | 0 | Common | Form 4 ↗ |
| Minnie Baylor-Henry | Director | 2026-05-14 | A | 4,137 | 0 | 0 | Common | Form 4 ↗ |
| Gary J. Pruden | Director | 2026-05-14 | A | 4,137 | 0 | 0 | Common | Form 4 ↗ |
| Julie McHugh | Director | 2026-05-14 | A | 4,137 | 0 | 0 | Common | Form 4 ↗ |
| Samuel Leno | Director | 2026-05-14 | A | 4,137 | 0 | 0 | Common | Form 4 ↗ |
| Dr. Phuong Khanh (P.K.) Morrow | Director | 2026-05-14 | A | 4,137 | 0 | 0 | Common | Form 4 ↗ |
| Kimberly Brown | Chief Accounting Officer | 2026-08-17 | D | 463 | 101 | 46,721 | Common | Form 4 ↗ |
| Ludger Dinkelborg | See Remarks | 2026-08-17 | D | 2,536 | 101 | 255,908 | Common | Form 4 ↗ |
| Robert Marshall Jr. | CFO and Treasurer | 2026-08-31 | D | 721 | 101 | 72,792 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (78 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Ludger Dinkelborg. DEF 14A, filed 2026-03-20. Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023” · page 53. As printed: 15,259,597. View filing ↗
- Section 01, Brian Markison. DEF 14A, filed 2026-03-20. Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023” · page 53. As printed: 13,919,738. View filing ↗
- Section 01, Paul Blanchfield. DEF 14A, filed 2026-03-20. Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023” · page 53. As printed: 5,435,275. View filing ↗
- Section 01, Robert Marshall Jr.. DEF 14A, filed 2026-03-20. Section “Our Named Executive Officers”. As printed: 5,194,964. View filing ↗
- Section 01, Daniel Niedzwiecki. DEF 14A, filed 2026-03-20. Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023” · page 53. As printed: 4,966,384. View filing ↗
- Section 01, Amanda Morgan. DEF 14A, filed 2026-03-20. Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023” · page 53. As printed: 3,304,547. View filing ↗
- Section 01, Mary Anne Heino. DEF 14A, filed 2026-03-20. Section “Summary Compensation Table for Fiscal Years 2025, 2024 and 2023” · page 53. As printed: 2,173,930. View filing ↗
- Section 03, Amanda Morgan OPTION. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Niedzwiecki RSU. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Paul Blanchfield RSU. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Amanda Morgan RSU. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Mary Anne Heino OPTION. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Marshall Jr. RSU. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Markison PSU. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Paul Blanchfield OPTION. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Marshall Jr. PSU. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Markison RSU. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Paul Blanchfield PSU. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Amanda Morgan PSU. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Ludger Dinkelborg OPTION. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Marshall Jr. OPTION. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Brian Markison OPTION. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Mary Anne Heino RSU. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Ludger Dinkelborg RSU. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Niedzwiecki PSU. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Niedzwiecki OPTION. DEF 14A, filed 2026-03-20. Section “Grants of Plan-Based Awards for Fiscal 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-03-20. Section “CEO Pay Ratio”. As printed: 79 : 1. View filing ↗
- Section 08, Dr. Phuong Khanh (P.K.) Morrow. DEF 14A, filed 2026-03-20. Section “Director Compensation”. As printed: 554,660. View filing ↗
- Section 08, Julie McHugh. DEF 14A, filed 2026-03-20. Section “Director Compensation”. As printed: 552,584. View filing ↗
- Section 08, Gary J. Pruden. DEF 14A, filed 2026-03-20. Section “Director Compensation”. As printed: 492,424. View filing ↗
- Section 08, Samuel Leno. DEF 14A, filed 2026-03-20. Section “Director Compensation”. As printed: 489,299. View filing ↗
- Section 08, Dr. James H. Thrall. DEF 14A, filed 2026-03-20. Section “Director Compensation”. As printed: 488,924. View filing ↗
- Section 08, Minnie Baylor-Henry. DEF 14A, filed 2026-03-20. Section “Director Compensation”. As printed: 480,757. View filing ↗
- Section 08, Heinz Mäusli. DEF 14A, filed 2026-03-20. Section “Director Compensation”. As printed: 479,924. View filing ↗
- Section 08, Julie Eastland. DEF 14A, filed 2026-03-20. Section “Director Compensation”. As printed: 476,591. View filing ↗
- Section 08, Dr. Gérard Ber. DEF 14A, filed 2026-03-20. Section “Director Compensation”. As printed: 465,799. View filing ↗
- Section 08, Brian A. Markison. DEF 14A, filed 2026-03-20. Section “Director Compensation”. As printed: 15,525. View filing ↗
- Section 08, Mary Anne Heino. DEF 14A, filed 2026-03-20. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Daniel Niedzwiecki 2026-04-17. Form 4, filed 2026-04-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Julie Eastland 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dr. James H. Thrall 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Mary Anne Heino 2026-05-14. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dr. Gérard Ber 2026-05-14. Form 4, filed 2026-06-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dr. Gérard Ber 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Heinz Christoph Maeusli 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Minnie Baylor-Henry 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary J. Pruden 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Julie McHugh 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Samuel Leno 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Dr. Phuong Khanh (P.K.) Morrow 2026-05-14. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kimberly Brown 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ludger Dinkelborg 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Marshall Jr. 2026-08-31. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-01. Item 5.07 · say-on-pay result. As reported: 96.54% (votes for as printed: 54,068,553). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-05. Item 5.07 · say-on-pay result. As reported: 95.32% (votes for as printed: 57,776,739.23). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-04-29. Item 5.07 · say-on-pay result. As reported: 97.67% (votes for as printed: 56,633,104.66). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 781,702 + equity 1,849,413 + all other 0 = 2,631,115, summed across the director compensation table rows.
- Exelixis, Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis's own proxy. As printed: 33,239,183. View filing ↗
- Halozyme Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Halozyme Therapeutics's own proxy. As printed: 23,166,223. View filing ↗
- BioMarin Pharmaceutical, Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceutical's own proxy. As printed: 21,927,563. View filing ↗
- United Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics's own proxy. As printed: 18,038,972. View filing ↗
- Exact Sciences, Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Exact Sciences's own proxy. As printed: 15,539,378. View filing ↗
- Waters, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Waters's own proxy. As printed: 13,973,044. View filing ↗
- Neurocrine Biosciences, Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. View filing ↗
- Ionis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Ionis Pharmaceuticals's own proxy. As printed: 13,350,777. View filing ↗
- Haemonetics, Section 10b CEO total. DEF 14A, filed 2026-06-09. CEO total compensation as printed in Haemonetics's own proxy. As printed: 12,044,701. View filing ↗
- Apellis Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals's own proxy. As printed: 10,957,451. View filing ↗
- Azenta, Section 10b CEO total. DEF 14A, filed 2025-12-18. CEO total compensation as printed in Azenta's own proxy. As printed: 10,371,414. View filing ↗
- Acadia Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals's own proxy. As printed: 8,256,518. View filing ↗
- Bio-Techne, Section 10b CEO total. DEF 14A, filed 2025-09-19. CEO total compensation as printed in Bio-Techne's own proxy. As printed: 8,151,181. View filing ↗
- Bio-Rad Laboratories, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Bio-Rad Laboratories's own proxy. As printed: 7,995,841. View filing ↗
- Alkermes, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alkermes's own proxy. As printed: 7,915,081. View filing ↗
- Sarepta Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sarepta Therapeutics's own proxy. As printed: 7,840,666. View filing ↗
- Repligen, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Repligen's own proxy. As printed: 6,114,771. View filing ↗
- Bruker, Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Bruker's own proxy. As printed: 4,706,388. View filing ↗
- Lantheus Holdings, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Lantheus Holdings, Inc.'s own proxy. As printed: 2,173,930. View filing ↗